Free tool
FAERS Monitor: Duobrii
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209354 or its brand name (Duobrii, Halobetasol Propionate, Tazarotene). Reports on generic versions are filed under their own applications.
Reports
198
Serious
66
33% of reports
Hospitalization
13
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- psoriasis50
- drug ineffective19
- pruritus16
- product dose omission issue15
- headache14
- nausea12
- diarrhoea11
- application site pain10
- rash10
- skin burning sensation10
- off label use9
- skin exfoliation9
- application site erythema8
- application site irritation8
- erythema8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2019 | 27 |
| 2020 | 31 |
| 2021 | 38 |
| 2022 | 35 |
| 2023 | 26 |
| 2024 | 20 |
| 2025 | 12 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site irritationSignal | 8 | 68.3 | 34.7 | 466 |
| application site painSignal | 10 | 48.2 | 26.4 | 417 |
| psoriasisSignal | 50 | 40.7 | 32.0 | 1,907 |
| application site erythemaSignal | 8 | 32.4 | 16.4 | 213 |
| skin burning sensationSignal | 10 | 14.8 | 8.1 | 116 |
| skin exfoliationSignal | 9 | 11.3 | 6.0 | 75 |
| product dose omission issueSignal | 15 | 5.4 | 3.3 | 50 |
| pruritusSignal | 16 | 4.4 | 2.8 | 40 |
| erythemaSignal | 8 | 4.1 | 2.1 | 16 |
| rashSignal | 10 | 2.4 | 1.3 | 7 |
| headacheSignal | 14 | 2.4 | 1.4 | 10 |
| diarrhoea | 11 | 1.8 | 1.0 | 3 |
| nausea | 12 | 1.6 | 0.9 | 2 |
| drug ineffective | 19 | 1.5 | 1.0 | 3 |
| off label use | 9 | 1.1 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.